நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத் Today - Breaking & Trending Today

Cadila Healthcare Ltd soars 1.24%, Gains for third straight session


Cadila Healthcare Ltd is quoting at Rs 635.2, up 1.24% on the day as on 12:49 IST on the NSE. The stock is up 75.13% in last one year as compared to a 55.93% gain in NIFTY and a 40.15% gain in the Nifty Pharma index.
Cadila Healthcare Ltd is up for a third straight session in a row. The stock is quoting at Rs 635.2, up 1.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.4% on the day, quoting at 15638.4. The Sensex is at 52049.43, up 0.39%. Cadila Healthcare Ltd has added around 11.61% in last one month.
Meanwhile, Nifty Pharma index of which Cadila Healthcare Ltd is a constituent, has added around 6.72% in last one month and is currently quoting at 14151.85, down 0.2% on the day. The volume in the stock stood at 27.72 lakh shares today, compared to the daily average of 98.83 lakh shares in last one month. ....

Cadila Healthcare Ltd , Nifty Pharma , Healthcare Ltd , Capital Market , Companies Based In Ahmedabad , Nifty 50 , National Stock Exchange Of India , Cadila Pharmaceuticals , Cadila Healthcare , Economy Of India , Stock Exchanges , Generic Pharmaceuticals , Integrated Circuits , Cadila Healthcare Ltd , S Ampp Bse Sensex , காடிலா சுகாதாரம் லிமிடெட் , நிஃப்டி பார்மா , சுகாதாரம் லிமிடெட் , மூலதனம் சந்தை , நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத் ,

Zydus Cadila receives USFDA tentative approval for Osimertinib Tablets

Read more about Zydus Cadila receives USFDA tentative approval for Osimertinib Tablets on Business Standard. Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some ....

Zydus Cadila , Osimertinib Tablets , Tagrisso Tablets , Capital Market , Companies Based In Ahmedabad , Organic Compounds , Chemical Compounds , Lung Cancer , Cadila Healthcare , Cadila Pharmaceuticals , Generic Pharmaceuticals , Formulation Manufacturing Facility , Zydus Cadila , ஜய்துச் காடிலா , மூலதனம் சந்தை , நிறுவனங்கள் அடிப்படையிலானது இல் அஹமதாபாத் ,